Department of Epidemiology, Johns Hopkins School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA.
Department of Health, Policy, and Management, Johns Hopkins School of Public Health, Baltimore, MD, USA.
BMC Public Health. 2021 May 12;21(1):901. doi: 10.1186/s12889-021-10977-5.
HIV services, like many medical services, have been disrupted by the COVID-19 pandemic. However, there are limited data on the impacts of the COVID-19 pandemic on HIV treatment engagement outcomes among transgender (trans) and nonbinary people. This study addresses a pressing knowledge gap and is important in its global scope, its use of technology for recruitment, and focus on transgender people living with HIV. The objective of this study is to examine correlates of HIV infection and HIV treatment engagement outcomes (i.e., currently on ART, having an HIV provider, having access to HIV treatment without burden, and remote refills) since the COVID-19 pandemic began.
We utilized observational data from the Global COVID-19 Disparities Survey 2020, an online study that globally sampled trans and nonbinary people (n = 902) between April and August 2020. We conducted a series of multivariable logistic regressions with lasso selection to explore correlates of HIV treatment engagement outcomes in the context of COVID-19.
Of the 120 (13.3%) trans and nonbinary people living with HIV in this survey, the majority (85.8%) were currently on HIV treatment. A smaller proportion (69.2%) reported having access to an HIV provider since COVID-19 control measures were implemented. Less than half reported being able to access treatment without burdens related to COVID-19 (48.3%) and having the ability to remotely refill HIV prescription (44.2%). After adjusting for gender in the multivariable models, younger age and anticipated job loss were significantly associated with not having access to HIV treatment without burden. Outcomes also significantly varied by geographic region, with respondents reporting less access to an HIV provider in nearly every region outside of South-East Asia.
Our results suggest that currently taking ART, having access to an HIV provider, and being able to access HIV treatment without burden and remotely refill HIV medication are suboptimal among trans and nonbinary people living with HIV across the world. Strengthening support for HIV programs that are well-connected to trans and nonbinary communities, increasing remote access to HIV providers and prescription refills, and providing socioeconomic support could significantly improve HIV engagement in trans and nonbinary communities.
艾滋病毒服务与许多医疗服务一样,受到了 COVID-19 大流行的影响。然而,关于 COVID-19 大流行对跨性别(trans)和非二进制人群的艾滋病毒治疗参与结果的影响,数据有限。本研究解决了一个紧迫的知识空白,并且具有重要的全球意义,它使用技术进行招募,重点关注感染艾滋病毒的跨性别者。本研究的目的是研究自 COVID-19 大流行开始以来,艾滋病毒感染和艾滋病毒治疗参与结果(即目前正在接受抗逆转录病毒治疗、有艾滋病毒提供者、在没有负担的情况下获得艾滋病毒治疗和远程续药)的相关因素。
我们利用了 2020 年全球 COVID-19 差异调查的观察性数据,这是一项在线研究,在 2020 年 4 月至 8 月期间在全球范围内对跨性别者和非二进制人群(n=902)进行了抽样。我们进行了一系列多变量逻辑回归分析,并使用套索选择法探讨了 COVID-19 背景下与艾滋病毒治疗参与结果相关的因素。
在本调查中,120 名(13.3%)感染艾滋病毒的跨性别者和非二进制者中,大多数(85.8%)正在接受艾滋病毒治疗。自 COVID-19 控制措施实施以来,报告能够获得艾滋病毒提供者的比例较小(69.2%)。不到一半的人报告说能够在没有与 COVID-19 相关负担的情况下获得治疗(48.3%),并且能够远程续药(44.2%)。在多变量模型中调整性别后,年轻和预期失业与无法在没有 COVID-19 负担的情况下获得艾滋病毒治疗显著相关。结果在不同地理区域也存在显著差异,除了东南亚以外的几乎每个区域的受访者都报告说获得艾滋病毒提供者的机会较少。
我们的结果表明,在全球范围内,感染艾滋病毒的跨性别者和非二进制者中,目前正在接受抗逆转录病毒治疗、获得艾滋病毒提供者、能够在没有负担的情况下获得艾滋病毒治疗以及远程续药和艾滋病毒药物的情况并不理想。加强与跨性别和非二进制社区联系紧密的艾滋病毒项目的支持,增加远程获得艾滋病毒提供者和处方续药的机会,以及提供社会经济支持,可能会显著改善跨性别和非二进制社区的艾滋病毒参与度。